Qiagen Stock - analyst consensus and risk profile in focus

Qiagen stock trades off recent levels with a relatively low beta and solid financial-health scores. A look at current analyst ratings, risk metrics and fundamentals shows how the diagnostics specialist is positioned against its biotech peers.

Edited by ad hoc news Analyst & Consensus Desk. Verified prior to publication on 06/21/2026, 11:00 UTC. Details in the imprint.

Qiagen (NL0012169213) is drawing attention this week as fresh data on analyst ratings, risk scores and financial strength frame the valuation debate. According to recent consensus snapshots and risk tools, the diagnostics specialist sits in the middle of the rating spectrum with below-market volatility.

How analysts rate Qiagen

Across the past twelve months, 12 Wall Street analysts have published recommendations on Qiagen stock, with the group split between cautious and positive views. According to MarketBeat, the distribution currently stands at 1 sell, 6 hold, 4 buy and 1 strong buy rating.

This mix leaves Qiagen in a neutral-to-constructive zone rather than a clear consensus favorite or underperformer. The breadth of views reflects both the company’s defensive diagnostics exposure and concerns about growth normalization after the pandemic testing boom.

Risk score and volatility metrics

Risk tools also provide a structured view on the stock’s profile. TradingKey assigns Qiagen NV a current risk assessment score of 9.21, placing it 1st out of 389 names in the Biotechnology and Medical Research industry in its framework. The methodology combines volatility, financial risk and other factors.

Qiagen’s beta is reported at 0.66, implying the shares typically move less than the broader market. According to TradingKey, this means the stock tends to lag in strong uptrends but can show smaller drawdowns in weak markets. Such behavior is consistent with a more defensive healthcare positioning.

What the financial-health scores show

Alongside the risk score, TradingKey cites a current financial-health score for Qiagen of 8.76, ranking the company 28th out of 389 peers in the same industry. The score aggregates profitability, balance sheet metrics and cash-generation indicators.

These rankings suggest a solid, if not top-decile, financial profile. Qiagen has historically emphasized recurring consumables revenue and disciplined capital allocation, which can support such scores in third-party models even as top-line growth fluctuates with testing demand.

Consensus, valuation and peer context

With the stock most recently quoted around the mid-$30s on the New York Stock Exchange, consensus valuation opinions remain differentiated. MarketBeat data show the average rating in the “Hold” area, while individual price targets cluster around current trading levels with modest upside or downside skews.

Against biotech peers, Qiagen’s combination of a sub-1.0 beta, strong risk and financial-health scores and balanced analyst views underpins its role as a defensive life-science tools name rather than a high-volatility pipeline play. For investors comparing sector exposure, this profile matters more than short-term price swings.

How Qiagen makes its money

Qiagen generates revenue primarily from sample preparation and molecular diagnostics solutions used in research and clinical labs worldwide. Key product families include QIAamp nucleic acid extraction kits, QIAcube automation systems and the QIAsymphony platform, complemented by test panels for infectious diseases and oncology.

Where the stock trades today

The shares of Qiagen (NL0012169213) trade on the New York Stock Exchange under the ticker QGEN at $36.95 as of 06/18/2026, 04:00 PM ET.

Key facts on Qiagen stock

• Company: Qiagen N.V.
• ISIN: NL0012169213
• WKN: A2DKCH
• Ticker: QGEN
• Venue: NYSE
• Price (as of 06/18/2026, 04:00 PM ET): 36.95 USD
• Market cap: 8,440,000,000 USD (as of 06/18/2026)
• Sector / Industry: Health Care / Biotechnology & Medical Research
• Index membership: Standard & Poor's 500 index
• Next earnings date: 07/30/2026

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.